Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions
This trial is active, not recruiting.
|Sponsor||M.D. Anderson Cancer Center|
|Start date||July 1999|
|End date||July 2017|
|Trial size||395 participants|
|Trial identifier||NCT00507182, HNS99-100, NCI-2012-01601|
The goal of this clinical research study is to test a new way to look for cancer and pre-cancerous tissue changes inside the mouth.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
Classification of Oral Lesions
time frame: 11 Years
Male or female participants at least 18 years old.
Inclusion Criteria: 1. Any person 18 years of age or older with a lesion of the oral mucosa. Persons with changes in existing lesions or those who develop new lesions can be re-evaluated, but it is not required. Exclusion Criteria:
|Official title||Fluorescence and Reflectance Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions|
|Principal investigator||Ann M. Gillenwater, MD|
|Description||Abnormal-looking areas (lesions) inside the mouth may be a sign of cancer or changes that may lead to cancer. These lesions may need to be removed. Researchers are looking for a practical way to tell early on whether these lesions are cancer or may become cancer. This study will test a technique called fluorescence spectroscopy, which is under research in this study. Each patient may have 1 to 5 lesions and several normal-looking areas inside the mouth exposed to a beam of light. The exposed tissues may emit very small amounts of light called fluorescence. This light is not seen by the eye but is detected by a computer. The small areas exposed to the light beam may then be removed. The patients who need surgery may have the small tested areas removed when the lesions are surgically removed. A small sample from a normal-looking area may also be removed during surgery. Patients who do not need surgery may simply have small samples taken from the lesions and a normal-looking area in the clinic rather than in the operating room. The tissues will be looked at under a microscope to see whether they are cancerous. These results will be compared with the spectroscopy results. If you are scheduled to participate in another MD Anderson study, Protocol 2008-0137 Entitled, "Phase Ib Study of Erlotinib Prior to Surgery in Patients with Head and Neck Cancer" (Study Chair: Dr. William William), some of your collected tissue samples may be shared with Dr. William for use on 2008-0137. This is an investigational study. About 395 patients will be consented and screened for this study, with about 381 to take full part in this study. All will be treated at MD Anderson.|
Call for more information